GlassScriptPhysician profile
Ronald B Moore
NPI 1578805123
$4,545.22
in general payments reported to CMS, 2019-2025
21 companies · $3,109 in 2025
The $3,109 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $165 · 2023: $187 · 2024: $625 · 2025: $3,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,397 · Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,396.67 |
| Food and Beverage | $1,524.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $2,496.38 | 2021-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $418.65 | 2021-2025 | |
| Corium, LLC | $348.23 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $196.15 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $187.51 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $165.82 | 2024-2025 | Auvelity |
| Noven Pharmaceuticals, INC. | $120.13 | 2024 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $119.94 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.38 | 2021 | |
| Noven Therapeutics, LLC | $49.27 | 2024-2025 | Secuado, Xelstrym |
| Teva Pharmaceuticals USA, INC. | $43.86 | 2023-2024 | Austedo Xr |
| Biogen, INC. | $43.80 | 2024 | |
| Vanda Pharmaceuticals INC. | $38.87 | 2021 | |
| Supernus Pharmaceuticals, INC. | $38.78 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $36.61 | 2023 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $35.67 | 2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $32.27 | 2021 | |
| Collegium Pharmaceutical, INC. | $26.94 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2025 | Cobenfy |
| Tris Pharma INC | $18.98 | 2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.